Assessing Neuren Pharmaceuticals (ASX:NEU) Valuation After Its Latest Annual Earnings Reset

Earnings trigger and why Neuren is on radar

Neuren Pharmaceuticals (ASX:NEU) has come into focus after releasing its full year 2025 results, reporting revenue of A$84.84 million and net income of A$30.44 million, both lower than the prior year.

See our latest analysis for Neuren Pharmaceuticals.

The share price reaction has been sharp, with a 1 day share price return of an 8.79% decline and a 30 day share price return of a 24.75% decline. The 1 year total shareholder return of 1.87% and 3 year total shareholder return of 64.18% suggest earlier optimism has faded recently as the latest earnings reset expectations and risk perceptions around Neuren’s growth story.

If you are weighing how this kind of earnings shock compares with other opportunities in healthcare, it may be worth scanning 10 healthcare AI stocks as a starting point for fresh ideas.

With earnings now sharply lower and the share price off its highs, the key question is whether Neuren’s current valuation reflects a temporary reset, or whether the market is already pricing in all the future growth potential.

Most Popular Narrative: 46.4% Undervalued

Neuren’s most followed valuation narrative puts fair value at A$23.45 per share, compared with the last close of A$12.56. This frames the recent share price pullback very differently to the headline earnings shock.

The analysts have a consensus price target of A$24.512 for Neuren Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of A$30.5, and the most bearish reporting a price target of just A$21.2.

Read the complete narrative. Read the complete narrative.

Curious how a high margin profile, shrinking share count and a richer future earnings multiple combine into that fair value line? The narrative leans heavily on earnings power several years out and assumes a very specific trade off between slower revenue in A$ terms and higher profitability. The interesting part is how those inputs get discounted back at just under 7% to bridge today’s price with that valuation.

Result: Fair Value of A$23.45 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, this hinges on key uncertainties, including Neuren’s reliance on Acadia for DAYBUE royalties and future FDA decisions that could shift timelines or earnings expectations.

Find out about the key risks to this Neuren Pharmaceuticals narrative.

Another View: Earnings Multiple Paints a Tougher Picture

The fair value estimate of A$23.45 suggests upside, but the earnings multiple tells a very different story. Neuren trades on a P/E of 52.3x, compared with 22.2x for the global pharmaceuticals group, a peer average of 18.5x and a fair ratio of 33.2x.

This gap means you are paying a much richer price for each A$ of earnings than both peers and the fair ratio imply, which could leave less room for error if forecasts change. So which lens do you rely on more when the signals conflict this clearly?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this mix of signals feels conflicted, do not wait for a consensus to form before you look closer. Check the 2 key rewards and weigh those positives for yourself.

Looking for more investment ideas?

If Neuren has sharpened your focus, do not stop here. Put that momentum to work by lining up a few more potential candidates now, while they are front of mind.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com